Fig. 3From: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in ChinaDeterministic sensitivity analysis of cost-effectiveness comparison of experimental group and control groupBack to article page